Skip to search formSkip to main contentSkip to account menu

JNJ 26854165

Known as: JNJ-26854165 
National Institutes of Health

Related topics

Related topics

4 relations
HDM2 Antagonist JNJ-26854165

Broader (2)

Radiation-Sensitizing AgentsTryptamines

Narrower (1)

Serdemetan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
linical Development Novel Tryptamine Derivative JNJ-26854165 Induces-Type p 53-and E 2 F 1-Mediated Apoptosis in Ther te Myeloid and Lymphoid Leukemias
ownload development of small-molecule activators of p53 is currently focused on malignancies containing a ype p53 genotype, which… 
2009
2009
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors.
3514 Background: JNJ-26854165 is a novel first-in-clinic oral Human Double Minute-2 (HDM-2) ubiquitin ligase antagonist. It… 
2009
2009
Gateways to clinical trials.
(+)-Dapoxetine hydrochloride, [(123)I]-BZA, 9-Aminocamptothecin; Abacavir sulfate/lamivudine, Adalimumab, Adefovir dipivoxil… 
2008
2008
JNJ-26854165 - a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies
AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA 1592 The Hdm2 oncogene is activated in a variety of cancers through… 
2008
2008
1LB Late Breaking First-in-Human study of the First-in-Class Hdm2 inhibitor JNJ-26854165
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)